Pharmacological Agents and Potential New Therapies in Pulmonary Arterial Hypertension.

Santos, Renata Trabach; de Sá Freire Onofre, Maria Eduarda; de Assis Fernandes Caldeira, Dayene; Klein, Adriane Bello; Rocco, Patricia Rieken Macedo; Cruz, Fernanda Ferreira; Silva, Pedro Leme

Santos, Renata Trabach; de Sá Freire Onofre, Maria Eduarda; de Assis Fernandes Caldeira, Dayene; Klein, Adriane Bello; Rocco, Patricia Rieken Macedo; Cruz, Fernanda Ferreira; Silva, Pedro Leme.

Afiliação

Santos RT; Laboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
de Sá Freire Onofre ME; Laboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
de Assis Fernandes Caldeira D; Laboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Klein AB; Laboratory of Cardiovascular Physiology and Reactive Oxygen Species, Department of Physiology, Institute of Basic Health Sciences, Federal University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.
Rocco PRM; Laboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Cruz FF; Laboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Silva PL; Laboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.

Curr Vasc Pharmacol ; 22(3): 155-170, 2024.

Article em En | MEDLINE | ID: mdl-38115617

ABSTRACT

ABSTRACT

Pulmonary arterial hypertension (PAH) is a progressive disease characterized by an imbalance between vasoactive mediators, which causes vascular remodeling, increased pulmonary vascular resistance, and right ventricular overload, ultimately leading to heart failure and death. A metabolic theory has been suggested to explain the pathophysiology of PAH whereby abnormalities in mitochondrial biogenesis can trigger a hyperproliferative and apoptosis-resistant phenotype in cardiopulmonary and malignant cells, leading to mitochondrial dysfunction, which in turn causes the Warburg effect. This can culminate in the mitophagy of pulmonary vessels and cardiomyocytes. The present narrative review focuses on the pathophysiology of PAH, the pharmacological agents currently available for its treatment, and promising and challenging areas of therapeutic investigation.

Assuntos

Anti-Hipertensivos; Hipertensão Arterial Pulmonar; Artéria Pulmonar; Humanos; Animais; Anti-Hipertensivos/uso terapêutico; Anti-Hipertensivos/efeitos adversos; Anti-Hipertensivos/farmacologia; Artéria Pulmonar/efeitos dos fármacos; Artéria Pulmonar/fisiopatologia; Artéria Pulmonar/metabolismo; Hipertensão Arterial Pulmonar/tratamento farmacológico; Hipertensão Arterial Pulmonar/fisiopatologia; Hipertensão Arterial Pulmonar/metabolismo; Transdução de Sinais/efeitos dos fármacos; Pressão Arterial/efeitos dos fármacos; Resultado do Tratamento; Remodelação Vascular/efeitos dos fármacos; Hipertensão Pulmonar/tratamento farmacológico; Hipertensão Pulmonar/fisiopatologia

Palavras-chave

Pulmonary hypertension; metabolic therapy; metabolism; new therapies; pharmacological agents; pulmonary arterial hypertension; regenerative medicine.

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Artéria Pulmonar / Hipertensão Arterial Pulmonar / Anti-Hipertensivos Limite: Animals / Humans Idioma: En Revista: Curr Vasc Pharmacol Assunto da revista: ANGIOLOGIA / FARMACOLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Brasil País de publicação: Emirados Árabes Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google